Molecules of Korolchuk IP-NFT (VITA-FAST)

Molecules of Korolchuk IP-NFT (VITA-FAST) Price

This cryptocurrency is not listed for trading or services on Gate.

$0.875152
+$0.001572(+0.18%)

Market Cap

$875.15K

24h High

$0.890133

24h Low

$0.857349

24h Turnover

$83.81

Total Supply

1.00M

Market Sentiment

Neutral

About Molecules of Korolchuk IP-NFT (VITA-FAST)

What is the project about? VitaDAO, a decentralized autonomous organization, introduces VITA-FAST, an innovative funding model for longevity research. Leveraging the Ethereum blockchain, VITA-FAST are ERC-20 tokens, signifying fractional ownership of the Intellectual Property Non-Fungible Token (IP-NFT) from longevity research conducted at the Korolchuk Lab, Newcastle University. VITA-FAST token holders gain governance rights over the IP, democratizing the decision-making processes in scientific research. 1. What is the project about? The project is focused on discovering and developing therapeutic compounds that can reactivate autophagy in Npc1 -/- cells. This involves screening bioactive and commercial small molecules in cell survival assays to identify potential autophagy activators that are not cytotoxic. The project uses advanced techniques like luciferase-p6 clearance and Halo-GFP-LC3 orthogonal assays for this purpose. 2. What makes your project unique? The project's uniqueness lies in its approach to identifying novel compounds that can induce autophagy in NPC1 -/- cells, a crucial process for treating Niemann-Pick Type C disease. Unlike existing treatments, this project employs high-throughput screening methods and innovative assays to discover compounds with high chemical variability and no similarity to existing autophagy inducers, opening up possibilities for new iIP. 3. History of your project. The project, led by Dr. Korolchuk and his team at Newcastle University, has progressed from generating data on thousands of compounds using advanced screening assays to identifying lead compounds with potential autophagic properties. It has evolved to include the synthesis of derivatives of these compounds and is now moving towards drug translation processes, including pharmacokinetics and scalability studies. 4. What’s next for your project? The next steps involve screening third-generation compounds, conducting in vitro and in vivo mo

Website

Explorers

Risk Disclosure

Cryptocurrencies are high-risk assets and are subject to significant price volatility. The value of digital assets may fluctuate sharply within a short period of time, and you may lose part or all of your investment principal. Past performance does not guarantee future results. Before engaging in any transaction, you should carefully assess your financial situation, investment experience, investment objectives, and risk tolerance, and ensure that you fully understand the characteristics and risks associated with cryptocurrencies. If necessary, you are advised to consult an independent professional advisor with the appropriate qualifications.

Disclaimer

The information provided on this page is for general reference only and does not constitute any form of investment, financial, legal, tax, or trading advice, nor does it constitute any offer, solicitation, or recommendation. Gate makes no representations or warranties regarding the accuracy, completeness, or timeliness of the relevant information and assumes no liability for any losses arising from users' own decisions based on such information. Gate products and services may be restricted in certain jurisdictions or for certain users. Before using the relevant services, please ensure compliance with applicable laws and regulations, and refer to the User Agreement for provisions regarding restricted regions and service limitations.